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Helping the sick satisfies a basic need in all of us and most societies have evolved ways of ensuring that the sick are looked after as well as possible. Industrialized countries have evolved complex health care systems, all of which have one thing in common: they are running out of money. The costs ofproviding health care are growing faster than the ability of national economies to sustain them. Funders, whether governments or insurers, have tried several different strategies to contain costs and make providers of care more accountable for the quality of care. In the UK, we have seen the introduction of a market in health care with funding of the system linked to various indicators of efficiency. Elsewhere in Europe, costcontainment measures are being implemented rigorously. New Zealand has embraced the UK market approach with enthusiasm while Australia is attempting to move away from traditional funding patterns by linking hospital income to case-mix measures such as diagnosis related groups (DRGs). Cost containment has been pursued most rigorously in the USA, where a complex system of financial incentives and penalties is used by the 'health care providers to control quality and limit operating cost. This system has come to be known as 'managed care'. A typical definition of managed care might describe it as a planned approach to the delivery of medical services which seeks to control costs and improve quality of health care by a variety of methods which might include controlling access to health care, case note review of treatment standards and the use of financial incentives to encourage efficiency. At the heart of the managed care system developed in the USA is the concept that what is best for the patient can be defined and turned into a protocol which can then be implemented efficiently.
Managed care, by its nature, alters the decisions doctors make about their patients. It seeks to limit clinical freedom where that freedom might result in inefficient or ineffective treatment being prescribed. It has been the subject of controversy in the USA, and its arrival in Europe is viewed with unease by JOURNAL OF MANAGFDCARE (l 'H7)I. 1-3 iDPcmcnProli:s9cDULaJ 1'R7 both clinicians and managers. Regardless of the uncertainty that exists in the minds of European clinicians about managed care, it remains an important force for the development of cost-effective practice.
It is unlikely to be ignored by funders of health care seeking to control spending.
In the UK a number of clinicians have themselves embraced the technique of the integrated care pathway (ICP), an example of the application of the managed care process. The principal driving force, so far, has been the notion that by the use of such techniques the delivery ofcare can be enhanced. Proof is beginning to emerge that outcomes may improve, and patients seem to appreciate the benefits of a planned approach to their treatment. What we have yet to see is the explicit use of managed care techniques in order to contain cost. It will certainly come. The potential advantages of managed care for the provider have not been ignored by the private health insurance industry. It sees, as do UK NHS purchasers, the opportunity to contain cost without necessarily affecting quality. N or has the pharmaceutical industry been slow to see that there are opportunities for it in this arena. There are a number of initiatives being created in the field of disease management, in which nurses, funded by the industry, undertake the care of a defined group of conditions (e.g. diabetes, asthma, benign prostatic hypertrophy, stoma care, etc.). While the industry rigorously asserts that these nurses have clinical freedom to use and recommend any product, it is unlikely to be coincidental that in all cases there is a clear match between the disease in question and the products of the company. Is this entirely altruistic? On the other hand, for the general practitioner or hospital specialist, the offer of a 'funded nurse' may permit care that could not be provided in any other way.
We believe it is timely to foster discussion on the implementation and design of managed care programmes. Weare intrigued as to how they might evolve in the face oftensions between clinical freedom and cost containment. We also wish to examine how such programmes might develop when applied to health care systems outside the USA.
The aim of this journal is to foster discussion about this emerging phenomenon and to allow colleagues throughout the world to contribute to the development of health care systems in an academically rigorous fashion. Both editors are, by training and inclination, clinicians rather than managers and are anxious that the clinical voice is heard as managed care programmes spread across more health systems. In the first issue, aspects of urology of relevance to the design of managed care programmes are considered. Future issues will concentrate on cancer care, heart disease and orthopaedics. We intend that this journal should contribute in a meaningful way to the improvement of health care in Europe and beyond.
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This first issue of the Journal of Managed Care sets out to consider the nature of managed care by exploring views of those involved in health care from a variety of perspectives. Managed care, by its very nature, means different things to different people; hence the need to cast a wide net to start to gain an understanding this multifaceted process. We consider, with the help of acknowledged experts, some of the benefits and also the risks.
William Armstrong (p.4) takes a look at some of the benefits that have been realized in the field of disease management in the USA and .discusses the potential transfer of techniques to the UK. In this respect the focus of disease management is the whole spectrum of care of patients suffering from chronic diseases such as asthma and diabetes. The principal philosophy of disease management is that it seeks to reduce complex and expensive treatment by prevention and education. Jonathan Belsey (p.12) highlights some of the potential pitfalls in managed care and offers a few pointers as to how to avoid or cope with them.
The first few issues of the journal will focus on opportunities for managed care in different clinical specialties. In this edition, we concentrate on the specialty of urology.
The integrated care pathway (ICP) is described by Sue Johnson (p.1S), who gives guidance on writing care pathways and emphasizes the need to involve all members of a team in creating such tools. The article exploring application of ICPs in the urology setting of transurethral prostatectomy (TURP) for symptomatic benign prostatic hypertrophy (BPH) considers more specific aspects of ICPs in UK surgical practice and demonstrates a clear reduction in length of stay with positive comments from patients and staff alike (p.3l).
Joe Smith from the Vanderbilt University Medical Centre, Tennessee, reveals how the application of a 'collaborative care program' (synonymous with ICP) can contain cost without sacrificing quality; British urologists will doubtless be intrigued by a 3-day stay for a radical prostatectomy (p.36).
Managed care programmes are likely to be targeted, initially at least, towards the common clinical scenarios, be they surgical procedures or medical conditions. In this way the benefits can be realized across the largest number of patients with consequently greater overall benefit. In the UK over 6S 000 patients undergo TURP annually at a cost in excess of £70m. The number of patients being referred for treatment is continually rising, partly because of changes in the demography of our population, where there has been an increase in the number of elderly patients more likely to suffer troublesome BPH, and partly due to greater health expectations of patients.
Purchasers may well see BPH management as an appropriate arena in which to initiate the managed care process. If managed care starts with an appraisal of options available in any given scenario then purchasers and indeed their providers must also consider what alternatives exist for the treatment of symptomatic BPH.
Three papers consider these alternative options. The authors have been quite dispassionate in their views, such that we have a fairly balanced (some might say jaundiced) view of the options. However, in this field, as in so many other areas of medicine and surgery where alternative treatments exist, there is
